Moreover, the compounds stimulated theproteasome to degrade model protein substrates involved in the developmentof neurodegenerative diseases, α-synuclein, and tau protein.In studies conducted with a mouse embryonic cell model, the activatorseffectively reduced the level of α-synuclein aggregates in thehippocampal neurons. The gene discussed is MAPT; the disease is neurodegenerative disease.